Other substances

Pomalidomide

A thalidomide analogue.

Phase of research

Potential treatment - theoretical effect

How it helps

Antiviral

Drug status

Used to treat other disease

1
 Supporting references
0
 Contradictory references
3
 AI-suggested references
0
 Clinical trials

General information

Pomalidomide on DrugBank
Pomalidomide on PubChem

Marketed as

POMALYST

 

Structure image - Pomalidomide

C1CC(=O)NC(=O)C1N2C(=O)C3=C(C2=O)C(=CC=C3)N

Supporting references

Link Tested on Impact factor Notes Publication date
Inhibition of SARS-CoV-2 main protease 3CLpro by means of α-ketoamide and pyridone-containing pharmaceuticals using in silico molecular docking
3CLpro Small molecule In silico 		in silico 2.46

Predicted to inhibit the SARS-CoV-2 3C-like protease.

 Jul/10/2020

AI-suggested references

Link Publication date
Melflufen or pomalidomide plus dexamethasone for patients with multiple myeloma refractory to lenalidomide (OCEAN): a randomised, head-to-head, open-label, phase 3 study.
Jan/12/2022
Lack of Induction of RBD-Specific Neutralizing Antibodies despite Repeated Heterologous SARS-CoV-2 Vaccination Leading to Seroconversion and Establishment of T Cell-Specific Memory in a Patient in Remission of Multiple Myeloma
Jun/30/2021
Inhibition of SARS-CoV-2 main protease 3CLpro by means of alpha-ketoamide and pyridone-containing pharmaceuticals using in silico molecular docking.
Jul/10/2020
Export (.csv)